Analysts think CGON stock price could increase by 119%
Jan 27, 2025, 12:25 PM
-18.80%
What does CGON do
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
9 analysts think CGON stock price will increase by 118.64%. The current median analyst target is $67.32 compared to a current stock price of $30.79. The lowest analysts target is $55.55 and the highest analyst target is $90.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
